

Role of clinical pharmacists in post-COVID management

Neda TANER^{1*}

¹ Department of Clinical Pharmacy, School of Pharmacy, İstanbul Medipol University, İstanbul, Türkiye

As the world begins to emerge from the COVID-19 pandemic, there is a critical need for healthcare providers to focus on post-COVID management. Clinical pharmacists can play a vital role in this effort, as they possess unique skills and expertise in medication management, patient education, and collaborative care.

One of the key challenges in post-COVID management is addressing the long-term effects of the disease, commonly known as long COVID. Clinical pharmacists can help by assessing and managing the pharmacological treatment of these chronic conditions, as well as monitoring for potential drug interactions and adverse effects.

In addition, clinical pharmacists can provide education to patients and other healthcare providers about the proper use of medications and the importance of medication adherence. This is especially important in the post-COVID era, as many patients may have experienced disruptions in their healthcare during the pandemic and may need support to resume their medication regimens.

Finally, clinical pharmacists can work collaboratively with other healthcare providers, such as physicians and nurses, to optimize medication therapy and ensure that patients receive the best possible care. This includes reviewing medication orders, monitoring drug therapy, and providing recommendations for dose adjustments or alternative treatments.

In conclusion, clinical pharmacists are well-positioned to play a critical role in post-COVID management. By leveraging their unique skills and expertise, they can help to address the long-term effects of the disease, provide education to patients and healthcare providers, and work collaboratively to optimize medication therapy.

Key words: COVID-19, clinical pharmacist

*Corresponding Author: E-mail: ntaner@medipol.edu.tr

REFERENCES

1. Forni V, Forni G, Torrabadella P. The role of pharmacists during the COVID-19 pandemic: A scoping review of the international literature. *Res Social Adm Pharm.* 2021 Jan 1;17(1):1799-806. <https://doi.org/10.1016/j.sapharm.2020.07.003>
2. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. *J R Soc Med.* 2021;114(9):428-442. doi:10.1177/01410768211032850
3. Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. *Curr Res Pharmacol Drug Discov.* 2022;3:100086. doi:10.1016/j.cr-phar.2022.100086
4. Altmann DM, Boyton RJ. Decoding the unknowns in long covid. *BMJ.* 2021;372:n132. Published 2021 Feb 4. doi:10.1136/bmj.n132